Tim Kong

15PUBLICATIONS
114CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classifiedMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 22, 2026
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors.

|Jun 25, 2026
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms.

|Apr 13, 2026
ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe.

Juliet Guay, Hellen Kuasne, Catherine Chabot

|Jan 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.

Tim Kong, Alex Mabry, Maureen Highkin

|Jan 17, 2025
RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia.

Tim Kong, Angelo B A Laranjeira, Christopher T Letson

|Nov 26, 2024
RSK1 dependency in FLT3-ITD acute myeloid leukemia.

Tim Kong, Angelo B A Laranjeira, Christopher T Letson

Pageof 3

Frequent Collaborators

9 joint publications

Stephen T Oh

6 joint publications

Sidong Huang

3 joint publications

Grant A Challen

2 joint publications

Yibo Xue